BRD3308

BRD3308 is a highly selective inhibitor of histone deacetylase 3 (HDAC3) with an IC₅₀ value of 65 nM for HDAC3 vs. IC₅₀ values of 1.08 μM and 1.15 μM for HDAC1 and HDAC2, respectively. BRD3308 protected pancreatic β cells, suppressing inflammatory cytokine-induced apoptosis and increasing insulin release without the toxicity associated with HDAC1 and HDAC2 inhibitors. In a rat model of type 2 diabetes, BRD3308 reduced hyperglycemia and increased insulin secretion without affecting weight gain. In another study, BRD3308 was found to activate HIV-1 transcription, disrupting HIV-1 latency.

BRD3308 is a highly selective inhibitor of histone deacetylase 3 (HDAC3).

BRD3308 promotes outgrowth of HIV-1 (human immunodeficiency virus 1) from inactive infected patient cells. It helps to increase β-cell proliferation.